Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1RN | P18510 | 9/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 9/20 | 0.55 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.53 |
| ▸ | CTSC | P53634 | 2/20 | 0.50 |
| ▸ | ECE1 | P42892 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2183858 | 0.96 | IL1RN (0.52) | IL1RNERAP2NPBWR1ERAP1KISS1R | |
| SCHEMBL2183137 | 0.89 | CTSC (0.61) | CTSCECE1 | |
| SCHEMBL10750299 | 0.88 | CTSC (0.54) | IL1RNERAP2ERAP1CTSCECE1 | |
| SCHEMBL16468415 | 0.86 | GHSR (0.51) | NPBWR1KISS1R | |
| SCHEMBL29987530 | 0.85 | ECE1 (0.64) | IL1RNERAP2ERAP1ECE1 | |
| SCHEMBL31247322 | 0.85 | ERAP2 (0.66) | IL1RNERAP2ERAP1KISS1RECE1 | |
| SCHEMBL5557252 | 0.85 | CTSC (0.61) | CTSCECE1 | |
| SCHEMBL30051545 | 0.84 | ECE1 (0.65) | IL1RNERAP2ERAP1ECE1 | |
| SCHEMBL30051718 | 0.84 | ERAP2 (0.64) | IL1RNERAP2ERAP1ECE1 | |
| SCHEMBL30169818 | 0.84 | ERAP2 (0.64) | IL1RNERAP2ERAP1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | IL1RN 3251/4885ERAP2 1822/4885NPBWR1 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.